Amgen Gets Panitumumab Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's panitumumab has an estimated mid-September user fee date under FDA priority review for metastatic colorectal cancer patients failing prior chemotherapy, the company announced June 12
You may also be interested in...
Amgen Vectibix Approved For Metastatic Colorectal Cancer
The first entirely human anti-EGFR antibody will launch in early or mid-October.
Amgen Vectibix Approved For Metastatic Colorectal Cancer
The first entirely human anti-EGFR antibody will launch in early or mid-October.
Amgen Licenses Erbitux-Related Patent After ImClone Court Loss
Amgen's competing anti-EGFR monoclonal antibody has Sept. 28 user fee date.